Affimed Therapeutics B.V. | Ownership
Companies that own Affimed Therapeutics B.V.
Wellington Management Co. LLP
6,914,340
11.08%
284,148
0.01%
06/30/2018
Bain Capital Public Equity LP
3,209,013
5.14%
0
1.08%
06/30/2018
Millennium Management LLC
2,415,947
3.87%
-141,364
0.02%
06/30/2018
Tekla Capital Management LLC
1,624,792
2.6%
-180,532
0.28%
06/30/2018
Telemetry Investments LLC
452,655
0.73%
-92,345
2.93%
06/30/2018
Morgan Stanley & Co. LLC
414,588
0.67%
87,518
0%
06/30/2018
Baker Bros. Advisors LP
400,000
0.64%
0
0.01%
06/30/2018
Eversept Partners LLC
386,862
0.62%
0
1.12%
06/30/2018
OrbiMed Advisors LLC
326,650
0.52%
0
0.02%
06/30/2018
Dimensional Fund Advisors LP
319,871
0.51%
0
0%
06/30/2018
| Address |
Technologiepark
Heidelberg Baden Wuerttemberg 69120
Germany
|
|
Employees
|
- |
| Website |
http://www.affimed.com |
| Updated |
07/08/2019 |
| Affimed NV is a clinical stage biopharmaceutical company, which engages in discovering and developing highly targeted cancer immunotherapies. The company has three proprietary platform technologies which includes: NK-cell TandAbs, T-cell TandAbs and Trispecific Abs. The company was founded in 2000 and is headquartered in Heidelberg, Germany. |
